EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Physiologically Based Pharmacokinetic Modeling of Fruquintinib and Its Metabolite to Assess Drug–Drug Interaction Liability as an Object or Precipitant

Ian E Templeton iD, Hannah M Jones, Caly Chien iD, Neeraj Gupta iD, Xiaofei Zhou iD

CPT: Pharmacometrics & Systems Pharmacology · 2026-11 · 15 (11)

DOI: 10.1002/psp4.70356 ↗

Kurz gefasst

Fachartikel in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, online erschienen am 11.11.2026. Verfasst von Ian E Templeton und 4 weiteren Autor:innen. Beteiligte Einrichtung: Certara UK Limited, Simcyp Division, Sheffield, UK. Hauptthemen laut MEDLINE: Benzofurans, Quinazolines, Models, Biological. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: HUTCHMED International Corporation & Takeda Pharmaceuticals U.S.A. Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Fruquintinib is approved, including in the United States and Europe, for previously treated metastatic colorectal cancer, regardless of biomarker status. Using in vitro and clinical data, physiologically based pharmacokinetic (PBPK) models were developed for fruquintinib and M11, a major metabolite of fruquintinib. The models were applied to evaluate the potential impact of strong/moderate/weak cytochrome P450 (CYP) and 3A4 (CYP3A4) inhibitors and inducers on the pharmacokinetics of fruquintinib and M11. In addition, the PBPK models were applied to evaluate the potential for P‐glycoprotein or breast cancer resistance protein (BCRP)‐mediated drug–drug interactions, with fruquintinib and M11 as precipitants (inhibitors). The simulations indicated that the changes in plasma exposure of fruquintinib area under the curve (AUC) geometric mean ratio (GMR) during administration with strong/moderate/weak inhibitors of CYP3A4 are negligible (< 1.25), and M11 interactions are weak with strong inhibition. Simulated changes in plasma exposure of fruquintinib in the presence of rifampin (a strong CYP3A4 and moderate CYP2C9 inducer) were > 0.20, but ≤ 0.50 (no significant change in M11). Fruquintinib AUC GMRs were > 0.50, but ≤ 0.80 with moderate CYP3A4 inducers, while the ratio fell between > 0.80 and 1.00 in the presence of weak CYP3A4 inducers. The effects of fruquintinib on the pharmacokinetics of P‐glycoprotein or BCRP substrates were not clinically significant. These analyses support avoiding concomitant use of strong, and if possible, moderate CYP3A4 inducers with fruquintinib. In addition, no dose adjustments for fruquintinib are required in the presence of CYP3A4 inhibitors, or for medications that are substrates of P‐glycoprotein or BCRP when used concomitantly with fruquintinib.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BenzofuransQuinazolinesModels, BiologicalDrug InteractionsHumansCytochrome P-450 CYP3A InducersCytochrome P-450 CYP3A InhibitorsCytochrome P-450 CYP3ANeoplasm ProteinsATP Binding Cassette Transporter, Subfamily G, Member 2Area Under CurveColorectal NeoplasmsATP Binding Cassette Transporter, Subfamily B, Member 1Computer SimulationRifampin

Stichwörter der Autor:innen

CYPdrug–drug interactionmetabolitephysiologically based pharmacokinetic modelingpredictionsimulationtransporter

Substanzen

BenzofuransQuinazolinesHMPL-013Cytochrome P-450 CYP3A InducersCytochrome P-450 CYP3A InhibitorsCytochrome P-450 CYP3ANeoplasm ProteinsATP Binding Cassette Transporter, Subfamily G, Member 2ABCG2 protein, humanCYP3A4 protein, human

Autor:innen und Institutionen

  • Certara UK Limited, Simcyp Division, Sheffield, UK.
  • HUTCHMED, Florham Park, New Jersey, USA.
  • Takeda Development Center Americas, Inc. (TDCA), Cambridge, Massachusetts, USA.

ORCID-Profile: Ian E Templeton, Caly Chien, Neeraj Gupta, Xiaofei Zhou

Förderung

  • HUTCHMED International Corporation & Takeda Pharmaceuticals U.S.A. Inc.

Zitieren

APA

Templeton, I. E., Jones, H. M., Chien, C., Gupta, N., & Zhou, X. (2026). Physiologically Based Pharmacokinetic Modeling of Fruquintinib and Its Metabolite to Assess Drug–Drug Interaction Liability as an Object or Precipitant. CPT: Pharmacometrics & Systems Pharmacology, 15(11). https://doi.org/10.1002/psp4.70356

Vancouver

Templeton IE, Jones HM, Chien C, Gupta N, Zhou X. Physiologically Based Pharmacokinetic Modeling of Fruquintinib and Its Metabolite to Assess Drug–Drug Interaction Liability as an Object or Precipitant. CPT: Pharmacometrics & Systems Pharmacology. 2026;15(11). doi:10.1002/psp4.70356

BibTeX
@article{Templeton2026,
  author = {Templeton, Ian E and Jones, Hannah M and Chien, Caly and Gupta, Neeraj and Zhou, Xiaofei},
  title = {Physiologically Based Pharmacokinetic Modeling of Fruquintinib and Its Metabolite to Assess Drug–Drug Interaction Liability as an Object or Precipitant},
  journal = {CPT: Pharmacometrics & Systems Pharmacology},
  year = {2026},
  volume = {15},
  number = {11},
  doi = {10.1002/psp4.70356}
}
Kostenlos starten →